HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced an EVT Execute collaboration with Beyond Batten Disease Foundation (“BBDF”) aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder.
“We are pleased to welcome Beyond Batten Disease Foundation as a new partner and join in the effort to develop therapies against this rare disease. We are confident that with our world-leading drug discovery platform and expertise significant progress can be made in this programme and collaboration.”
Under the terms of the agreement, Evotec will develop and use in vivo mechanistic and efficacy assays to assess the translational potential of fundamental and early drug discovery findings emerging from academic institutions in the United States and Europe. The goal of this programme is to leverage Evotec’s broad discovery expertise and experience to validate findings and to initiate their translation from bench to bedside. Evotec joins a dynamic, multidisciplinary pipeline of foundation-led activity designed to prioritise therapeutically promising findings while de-emphasising programmes that under-perform in the translational space. The collaboration includes substantial research funding to Evotec and runs to the end of 2017, with an option to extend beyond this period.
Further financial details were not disclosed.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are pleased to welcome Beyond Batten Disease Foundation as a new partner and join in the effort to develop therapies against this rare disease. We are confident that with our world-leading drug discovery platform and expertise significant progress can be made in this programme and collaboration.”
Craig Benson, BBDF Founder and Chairman of the Board added: “BBDF is delighted to be partnering with a global industry leader like Evotec to further our mission to eradicate juvenile Batten disease. Our goal is to leverage their expertise to advance our research into clinical trials, and ultimately a treatment, as quickly as possible.”
ABOUT BATTEN DISEASE
Juvenile Batten (CLN3) disease is a rare, fatal, inherited disorder of the nervous system that usually begins in childhood. The first symptom is usually progressive vision loss in previously healthy children followed by personality changes, behavioural problems and slowed learning. Seizures and psychosis can begin at any time during the course of disease. Progressive loss of motor functions (movement and speech) start with clumsiness, stumbling and Parkinson-like symptoms. Eventually, those affected become wheelchair-bound are bedridden and die prematurely.
ABOUT BEYOND BATTEN DISEASE FOUNDATION
Beyond Batten Disease Foundation (“BBDF”) is the world’s largest organisation dedicated to funding research for a treatment or cure for juvenile Batten (CLN3) disease. Since its inception in 2008, BBDF has applied over $ 15.5 m. BBDF is spearheading a unique, cohesive strategy, incorporating independent scientific resources and collaboration with related organizations to drive research in juvenile Batten Disease. For more information, visit www.beyondbatten.org.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease. For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart
Contacts
Evotec AG
Gabriele Hansen
VP Corporate Communications & Investor Relations
Phone: +49.(0)40.56081-255
gabriele.hansen@evotec.com
Help employers find you! Check out all the jobs and post your resume.
